# Arazlo® (tazarotene) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tazarotene

> Arazlo® (tazarotene), sponsored by GRI Bio, Inc. (GRI): 12 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Arazlo® (tazarotene) |
| Codes | GRI-0621 |
| Sponsor | GRI Bio, Inc. (GRI) https://sec-api.dev/companies/gri/catalysts |
| Indications | inflammatory, fibrotic and autoimmune diseases, today |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-14, last confirmed 2025-03-14.
- SEC Form 10-K (accession 0001824293-25-000050): "In December 2023, we commenced enrollment in our Phase 2a trial in IPF patients and we expect topline results from this trial to be available in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/ck0001824293-20241231.htm
- SEC Form 10-K (accession 0001824293-25-000050): "In December 2023 we commenced enrollment for our Phase 2a trial." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/ck0001824293-20241231.htm

### November 14, 2024: earnings report

- Status: completed. Date confidence: exact.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001824293-24-000153): "GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis" https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/ex991_pressreleaseq32024ea.htm

### Q1 2025: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0001824293-24-000151): "Based on our current enrollment projections, we now expect interim data from this trial to be available in the first quarter of 2025 and topline results to be available in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429324000151/ck0001824293-20240930.htm

### March 17, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-03-17, last confirmed 2025-03-17.
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000053): "GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")" https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/ex991_pressreleaseye24earn.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-14, last confirmed 2025-07-31.
- Press release filed with the SEC (EX-99) (accession 0001824293-24-000153): "Topline data of GRI-0621 readout expected in Q2 2025" https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/ex991_pressreleaseq32024ea.htm
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000094): ""Our team remains focused on the successful execution of the study and look forward to reporting topline data later this year, and hope to be able to report findings regarding pulmonary function in the coming weeks."" https://www.sec.gov/Archives/edgar/data/1824293/000182429325000094/ex991_pressrelease6weekbio.htm

### Q2 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-03-17, last confirmed 2025-05-15.
- SEC Form 10-Q (accession 0001824293-25-000073): "Based on our current enrollment projections, we expect interim data from this trial to be available in the second quarter of 2025 and topline results to be available in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000073/ck0001824293-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000053): "Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively" https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/ex991_pressreleaseye24earn.htm

### May 15, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-05-15, last confirmed 2025-05-15.
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000072): "GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025" https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/ex991_pressreleaseq125earn.htm

### Q3 2025: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-03-17, last confirmed 2025-03-17.
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000053): "We continue to make strides towards our anticipated interim data readout and topline data readout which remains on track for the second and third quarter of 2025, respectively." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/ex991_pressreleaseye24earn.htm

### Q3 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-03-14, last confirmed 2025-06-26.
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000082): "6-week interim biomarker data (n=24) expected in July 2025 and topline data expected in Q3 2025" https://www.sec.gov/Archives/edgar/data/1824293/000182429325000082/ex991_pressrelease6weeksaf.htm
- SEC Form 10-K (accession 0001824293-25-000050): "Based on our current projections, we expect topline results from this trial to be available in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/ck0001824293-20241231.htm
- SEC Form 10-K (accession 0001824293-25-000050): "Table of Contents current projections, we expect topline results from this trial to be available in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/ck0001824293-20241231.htm

### Nov 2025: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2025-11-14, last confirmed 2025-11-14.
- SEC Form 10-Q (accession 0001824293-25-000151): "We expect to release topline results from the Phase 2a biomarker study by the end of November 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000151/ck0001824293-20250930.htm

### December 10, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2025-03-14, last confirmed 2025-12-10.
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000167): "LA JOLLA, CA, December 10, 2025 -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced positive topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF")." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000167/ex991_pressreleasetoplined.htm
- SEC Form 10-K (accession 0001824293-25-000050): "In addition, we previously expected topline results from our Phase 2a trial for GRI-0621 to be available in the fourth quarter of 2024 and this has since been delayed to the third quarter of 2025 primarily as a result of delayed enrollment." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/ck0001824293-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000094): "Topline results from the Phase 2a biomarker study are expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000094/ex991_pressrelease6weekbio.htm
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000072): "Topline results from the Phase 2a biomarker study are expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/ex991_pressreleaseq125earn.htm
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000094): "Phase 2a study fully enrolled; Topline data on track for Q3 2025" https://www.sec.gov/Archives/edgar/data/1824293/000182429325000094/ex991_pressrelease6weekbio.htm
- Press release filed with the SEC (EX-99) (accession 0001824293-25-000082): "Topline results from the Phase 2a biomarker study are expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000082/ex991_pressrelease6weeksaf.htm
- SEC Form 10-Q (accession 0001824293-25-000106): "Topline results from the Phase 2a biomarker study are expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000106/ck0001824293-20250630.htm
- SEC Form 10-K (accession 0001824293-25-000050): "In December 2023, we commenced enrollment in our Phase 2a trial in IPF patients and we expect topline results from this trial to be available in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/ck0001824293-20241231.htm
- SEC Form 10-K (accession 0001824293-25-000050): "We intend to conduct a randomized double-blind placebo-controlled Phase 2a trial in approximately 36 patients with IPF with topline data expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/ck0001824293-20241231.htm

### May 14, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-05-14, last confirmed 2026-05-14.
- Press release filed with the SEC (EX-99) (accession 0001824293-26-000046): "GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline" https://www.sec.gov/Archives/edgar/data/1824293/000182429326000046/ex991_pressreleaseq126earn.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tazarotene.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Arazlo® (tazarotene) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tazarotene

```bibtex
@misc{secapidev_pdufa_tazarotene_20261116,
  title        = {Arazlo® (tazarotene) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tazarotene}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tazarotene_20261116","title":"Arazlo® (tazarotene) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tazarotene","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
